Literature DB >> 6095665

Ovarian cancer: diagnosis and management.

H R Barber.   

Abstract

Ovarian cancer is the leading cause of death from gynecological cancer in the United States. Early diagnosis is a matter of chance rather than a scientific method. Although it is stated that there are no symptoms in the early stage of ovarian cancer, a careful history often reveals vague gastrointestinal symptoms that have been persistent. Surgery is the treatment of choice for ovarian cancer, with chemotherapy employed as adjunctive therapy. Radiation therapy has limited application in treating common epithelial cancers but is valuable in the management of germ cell and gonadal stromal tumors. Of the numerous laboratory tests available, only immunologic assay appears to have the potential for making an early diagnosis and monitoring treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095665     DOI: 10.1016/0002-9378(84)90380-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

Review 1.  WITHDRAWN: Robotic surgery for benign gynaecological disease.

Authors:  Hongqian Liu; DongHao Lu; Gang Shi; Huan Song; Lei Wang
Journal:  Cochrane Database Syst Rev       Date:  2014-12-11

Review 2.  WITHDRAWN: Robotic assisted surgery for gynaecological cancer.

Authors:  Gang Shi; DongHao Lu; Zhihong Liu; Dan Liu; Xiaoyan Zhou
Journal:  Cochrane Database Syst Rev       Date:  2014-12-11

3.  Surgery in postmenopausal women--the value of transvaginal sonography.

Authors:  A Schoenfeld; H Levavi; J Ovadia
Journal:  Surg Endosc       Date:  1990       Impact factor: 4.584

4.  Prevalence, incidence, and natural history of simple ovarian cysts among women >55 years old in a large cancer screening trial.

Authors:  Robert T Greenlee; Bruce Kessel; Craig R Williams; Thomas L Riley; Lawrence R Ragard; Patricia Hartge; Saundra S Buys; Edward E Partridge; Douglas J Reding
Journal:  Am J Obstet Gynecol       Date:  2010-01-22       Impact factor: 8.661

5.  The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice.

Authors:  W Walker; G Gallagher
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.